SPL.AX - Starpharma Holdings Limited

ASX - ASX Delayed Price. Currency in AUD

Starpharma Holdings Limited

4-6 Southampton Crescent
Abbotsford, VIC 3067
Australia
61 3 8532 2700
http://starpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Jacinth K. FairleyCEO, MD & Exec. DirectorN/AN/A1963
Mr. Nigel J. Baade B.Com, CPA, Grad. Dip.CFO & Company Sec.N/AN/AN/A
Dr. A. Eglezos BSc(Hons),Ph.D., MBAVP of Bus. Devel.N/AN/AN/A
Dr. Jeremy R. Paull BSc (Hons), Ph.D.VP of Devel. & Regulatory AffairsN/AN/AN/A
Dr. David J. Owen BSc(Hons) Ph.D.VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Corporate Governance

Starpharma Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.